10% Encapsulated 4-Butylresorcinol
10% Encapsulated 4-Butylresorcinol
Nano-micelle self-assembled colloidal delivery system; features solubilization capability, structural stability, low toxicity and small particle size; lower molecular weight enables faster penetration; structurally similar to human liposomes
Product overview
4‑Butylresorcinol is a new-generation tyrosinase inhibitor carefully studied via the quantitative structure-activity relationship (QSAR) method in medicinal chemistry. It delivers remarkable whitening, spot-fading and depigmenting effects in cosmetic and cosmeceutical formulations. Featuring high efficacy and favorable safety profile, 4‑butylresorcinol stands out among whitening actives and serves as an ideal option for skincare users
Composition Information
| Component Type | INCI | CAS | EC |
|---|---|---|---|
| Components | 4-BUTYLRESORCINOL | 18979-61-8 | |
| Components | LECITHIN | 8002-43-5 / 8030-76-0 (soybean) | 232-307-2 / 310-129-7 |
| Components | GLYCERIN | 56-81-5 | 200-289-5 |
Mechanism of Action
1. Pre-pigment-synthesis stage: Interfere with the synthesis and glycosylation of tyrosinase and reduce its uptake by melanosomes.
2. Pigment-synthesis stage: Act as a competitive inhibitor of tyrosinase and TRP‑1 to reduce the production of pigment-related by-products.
3. Post-pigment-synthesis stage: Promote tyrosinase degradation and inhibit melanosome transport to keratinocytes.
4. Functional system: The nanomicelle colloid structure improves active ingredient penetration and prolongs the duration of skin-brightening effect.
Experimental Data
1. Comparative tyrosinase inhibition test: 10% butylresorcinol encapsulate shows 2.5× the potency of hydroquinone, 74× of kojic acid and 140× of arbutin in inhibiting human tyrosinase.
2. Pigment reversibility test: The brightening effect is dose-dependent. Skin tone gradually reverts after discontinuation without damaging melanocyte viability.
3. Human keratinocyte inhibition test: 10% butylresorcinol encapsulate exhibits lower suppression on human keratinocyte survival compared with hydroquinone.
Product specifications
| INCI Name: | 4-BUTYLRESORCINOL, LECITHIN, GLYCERIN |
|---|---|
| Source: | 4‑Butylresorcinol is a tyrosinase inhibitor developed based on QSAR quantitative structure-activity relationship research in medicinal chemistry. Taking 4‑butylresorcinol as the core active ingredient, it is prepared via nanomicelle encapsulation and delivery technology. |
| Recommended dosage: | 0.1‑10% |
| Appearance: | Pale yellow clear oily liquid with slight characteristic odor |
Key benefits
1. Potent tyrosinase inhibition; comparative tests demonstrate stronger inhibitory efficacy than hydroquinone, kojic acid and arbutin.
2. Whitening effect is dose-dependent and reversible without impairing the intrinsic viability of melanocytes.
3. Good cellular safety; compared with hydroquinone, it exhibits lower inhibitory effect on the viability of human keratinocytes.
4. Nanomicelle delivery system enhances active ingredient transport and improves spreadability and durability.
